Walleye Capital LLC Boosts Stock Position in Protara Therapeutics, Inc. $TARA

Walleye Capital LLC grew its position in shares of Protara Therapeutics, Inc. (NASDAQ:TARA) by 204.0% during the 1st quarter, Holdings Channel.com reports. The firm owned 443,401 shares of the company’s stock after acquiring an additional 297,525 shares during the period. Walleye Capital LLC’s holdings in Protara Therapeutics were worth $2,310,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of TARA. Janus Henderson Group PLC boosted its stake in Protara Therapeutics by 21.5% in the fourth quarter. Janus Henderson Group PLC now owns 5,141,616 shares of the company’s stock worth $27,379,000 after buying an additional 910,285 shares in the last quarter. Velan Capital Investment Management LP grew its position in Protara Therapeutics by 32.5% during the fourth quarter. Velan Capital Investment Management LP now owns 2,834,652 shares of the company’s stock valued at $15,109,000 after acquiring an additional 695,652 shares during the last quarter. Integral Health Asset Management LLC raised its stake in shares of Protara Therapeutics by 60.7% during the fourth quarter. Integral Health Asset Management LLC now owns 2,250,000 shares of the company’s stock worth $11,992,000 after acquiring an additional 850,000 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Protara Therapeutics by 5.7% during the third quarter. Vanguard Group Inc. now owns 1,904,156 shares of the company’s stock worth $8,283,000 after acquiring an additional 102,176 shares in the last quarter. Finally, AIGH Capital Management LLC bought a new stake in shares of Protara Therapeutics in the 1st quarter worth approximately $8,454,000. 38.13% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 16th. Oppenheimer lifted their target price on shares of Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. HC Wainwright reissued a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Cantor Fitzgerald restated an “overweight” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Finally, JPMorgan Chase & Co. reduced their price objective on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $26.25.

Protara Therapeutics Stock Performance

Shares of TARA stock opened at $4.04 on Friday. Protara Therapeutics, Inc. has a fifty-two week low of $2.97 and a fifty-two week high of $7.82. The stock has a 50 day moving average price of $4.23 and a two-hundred day moving average price of $5.18. The company has a market capitalization of $227.05 million, a P/E ratio of -3.01 and a beta of 1.48.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.31) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. As a group, equities analysts predict that Protara Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.